Applied DNA to Showcase Linea IVT as a High-yield, dsRNA-Mitigated Platform for the GMP Manufacture of RNA at the 4th Annual mRNA-based Therapeutics Summit
July 29th, 2024
News
All Categories
ACDL
APDN in the News
CertainT®
Coronavirus
Corporate/Financial News
Investors
Large-Scale DNA Production
Linear DNA
mpox
PGx
Press Release
Uncategorized
Vaccines
Applied DNA Enters into Multi-Year Commercialization Agreement with Indus Group for Large-Scale Implementation of CertainT Cotton Traceability
July 25th, 2024
U.S. Defense Logistics Agency Exercises 1-Year Option Period in Applied DNA Counterfeit Mitigation Contract
July 18th, 2024
Applied DNA and Alphazyme Conclude Linea™ RNAP Manufacturing Scale-Up Project, Deliver Substantial Improvement in Linea™ IVT Platform Economics
June 20th, 2024
Applied DNA Partners with GenXys Health Care Systems to Deploy Clinical Decision Support System for Pharmacogenetic (PGx) Testing
June 18th, 2024
Applied DNA Receives Approval for TR8™ Pharmacogenomic (PGx) Testing Service from New York State Department of Health
June 13th, 2024
Applied DNA Announces Notice of Allowance for U.S. Patent Covering Fundamental Aspect of its Linea™ IVT Platform
June 5th, 2024
Applied DNA Announces Pricing of $12 Million Public Offering
May 28th, 2024
Institute of Hematology and Blood Transfusion (Prague) to Present on Successful Use of Applied DNA’s Linea DNA™ for the Non-Viral Manufacture of CAR T-Cell Therapy for Refractory AML
May 13th, 2024